A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes

Coudeville, Laurent; André, Philippe; Bailleux, Fabrice; Weber, Françoise; Plotkin, Stanley А.

doi:10.4161/hv.6.10.12636

Cited by 32 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[73][74][75][76] Immunogenicity has been explored also in immunocompromised patients: in transplanted patients, [77][78] in HIV-infected patients, 79 and in cancer patients. 80 Immunogenicity profiles of ID vaccines are not inferior to IM vaccines, as proven by some recently 89 Tsang and collaborators performed a randomized, controlled, multicenter, phase II study in older adults (≥65 years of age) who were randomly assigned to ID vaccine with 15μg (HA)/strain (n=636), ID vaccine with 21μg HA/strain (n=634), standard IM vaccine with 15μg HA/strain (n=319) and high-dose IM vaccine with 60μg HA/strain (n=320), respectively.…”

Section: Cutaneous Drug and Vaccine Deliverymentioning

confidence: 99%

Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

Bragazzi

Orsi

Ansaldi

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Influenza is a highly contagious respiratory acute viral disease which imposes a very heavy burden both in terms of epidemiology and costs, in the developed countries as well as in the developing ones. It represents a serious public health concern and vaccination constitutes an important tool to reduce or at least mitigate its burden. Despite the existence of a broad armamentarium against influenza and despite all the efforts and recommendations of international organisms to broaden immunization, influenza vaccination coverage is still far from being optimal. This, taken together with logistic and technical difficulties that can result into vaccine shortage, makes intra-dermal (ID) vaccines, such as Fluzone® ID and Intanza®, particularly attractive. ID vaccines are comparable and, in some cases, superior to intra-muscular/sub-cutaneous vaccines in terms of immunogenicity, safety, reactogenicity, tolerability and cross-protection profiles, as well as in terms of patient preference, acceptance and vaccine selection. Further advances, such as Fluzone® ID with alternative B strains and Quadrivalent Fluzone® ID or the possibility of self-administering the vaccines, make influenza ID vaccines even more valuable.

show abstract

Section: Cutaneous Drug and Vaccine Deliverymentioning

confidence: 99%

Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

Bragazzi

Orsi

Ansaldi

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…When evaluating vaccination response to influenza, a serum antibody titer of ≥1:40 against the HA protein is considered to be clinically relevant, resulting in a 50% decrease in symptomatic infection and, therefore, serving as a correlate of protective immunity [107]. Recent analysis of published data indicates an even higher level of clinical protection, estimating that 70% of participants are protected at a titer of 1:40, with protection increasing gradually with higher titers [108].…”

Section: Serological Studiesmentioning

confidence: 99%

Maternal Influenza: Infection, Vaccination, and Compelling Questions

Manske¹

2016

Steps Forwards in Diagnosing and Controlling Influenza

View full text Add to dashboard Cite

Influenza presents a significant risk for increased morbidity and mortality to pregnant women and infants based on evidence from previous influenza pandemics, seasonal epidemics, and the recent H1N1 pandemic. Since 2004, influenza vaccine has been recommended for pregnant women during any trimester of pregnancy to reduce this risk. This chapter presents an overview of influenza risks associated with pregnancy as well as a review of our current understanding of vaccine effectiveness in pregnant women, neonates, and young infants. In addition, some of the current compelling questions related to influenza risk and prevention across all trimesters of pregnancy are explored.

show abstract

“…It is not known whether the licensing criteria applied to seasonal influenza vaccines are appropriate for pandemic influenza vaccines. Different criteria may be appropriate for different populations [128]. Furthermore, there is no known correlate for immunologic priming; this would be important for novel pandemic vaccines, which may not meet the classical criteria of HAI for immunogenicity, but prime for robust responses following administration of a booster vaccine.…”

Section: Immunogenicity-a Clear Understanding Of the Determinants Of mentioning

confidence: 99%

Refining the Approach to Vaccines Against Influenza a Viruses with Pandemic Potential

Czakó

Subbarao

2015

Future Virol.

View full text Add to dashboard Cite

Vaccination is the most effective strategy for prevention and control of influenza. Timely production and deployment of seasonal influenza vaccines is based on an understanding of the epidemiology of influenza and on global disease and virologic surveillance. Experience with seasonal influenza vaccines guided the initial development of pandemic influenza vaccines. A large investment in pandemic influenza vaccines in the last decade has resulted in much progress and a body of information that can now be applied to refine the established paradigm. Critical and complementary considerations for pandemic influenza vaccines include improved assessment of the pandemic potential of animal influenza viruses, proactive development and deployment of pandemic influenza vaccines, and application of novel platforms and strategies for vaccine production and administration.

show abstract

A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes

Cited by 32 publications

References 30 publications

Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview

Maternal Influenza: Infection, Vaccination, and Compelling Questions

Refining the Approach to Vaccines Against Influenza a Viruses with Pandemic Potential

Contact Info

Product

Resources

About